Moderna has received a major boost after its personalized mRNA cancer vaccine showed promising results in a late-stage clinical trial.
Shares of Moderna jumped more than 40% after the company and Merck announced positive results from their Phase 3 trial. Merck’s stock also rose sharply, gaining more than 10%.
The strong market reaction shows how important the results are for Moderna, which has been looking at cancer vaccines as a key part of its future.
Cancer Vaccine Trial Shows Positive Results
The vaccine is being developed by Moderna in partnership with Merck.
It combines Moderna’s personalized mRNA cancer vaccine with Merck’s cancer drug Keytruda.
More than 1,100 people took part in the Phase 3 trial.
The participants had a higher risk of melanoma returning after the cancer had been surgically removed.
The trial achieved its main goal. Patients who received the vaccine along with Keytruda stayed free of melanoma for longer than those who received Keytruda alone.
The combination also reduced the risk of melanoma spreading to distant parts of the body.
Why Did Moderna Stock Rise So Much?
Moderna’s shares saw a much bigger percentage jump than Merck’s largely because of the difference in their market sizes.
Before the rise, Moderna had a market value of around $25 billion, while Merck was valued at roughly $333 billion.
This means the same positive news can have a much larger impact on a smaller company’s stock price.
Moderna CEO Stephane Bancel described the results as an important moment for both medicine and patients.
How Does the Personalized Cancer Vaccine Work?
Unlike traditional treatments that are designed for a broad group of patients, Moderna’s vaccine is personalized for each person.
Doctors identify specific mutations in a patient’s tumour.
The vaccine is then designed to help the immune system recognise these unique markers.
The goal is to train the immune system to identify and attack cancer cells more effectively.
Keytruda is given alongside the vaccine to further help the immune system fight the cancer.
Is the Cancer Vaccine Ready for US Approval?
Not yet.
Although the Phase 3 results are encouraging, the trial is still studying other important outcomes, including whether the treatment can help patients live longer overall.
Moderna and Merck have not yet announced exactly when they will submit the treatment for approval in the US.
The companies are expected to discuss the results with regulatory authorities in the coming months and present more detailed data at an upcoming international medical meeting.
Why This Is Important for Moderna
The results are particularly significant for Moderna because investors have been closely watching its cancer vaccine programme.
The company has been exploring whether its mRNA technology, already widely known for vaccines, can also be used to develop treatments for cancer.
The positive Phase 3 results provide important evidence that the personalized mRNA approach can work in a large, late-stage clinical trial.
However, the treatment still needs more data and must go through the regulatory approval process before it can become available to patients.
For now, the results have strengthened hopes that personalized mRNA cancer vaccines could become an important part of future cancer treatment.
